Filing Flows › Acadia Pharmaceuticals (ACAD) › R&D spending
Acadia Pharmaceuticals (ACAD) R&D spending by quarter
Acadia Pharmaceuticals' R&D spending was $76.3M in Q3 2026 (third quarter 2026), -6% from Q2 2026. Over the last 7 quarters it ranged from $76.3M (Q3 2026) to $87.8M (Q3 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $76.3M | -6% | -13% |
| Q2 2026 | $81.6M | +6% | +5% |
| Q1 2026 | $76.9M | -9% | -2% |
| Q4 2025 | $84.8M | -3% | — |
| Q3 2025 | $87.8M | +13% | — |
| Q2 2025 | $78.0M | -0.4% | — |
| Q1 2025 | $78.3M | — | — |
Q3 2026 at a glance
Acadia Pharmaceuticals, Q3 2026: revenue $342M (+23% year over year), operating margin 21.0%, net earnings $53.5M, operating cash flow $11.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Acadia Pharmaceuticals' R&D spending?
Acadia Pharmaceuticals' R&D spending was $76.3M in Q3 2026 (third quarter 2026), -6% from Q2 2026.
How has Acadia Pharmaceuticals' R&D spending changed?
Over the last 7 quarters it ranged from $76.3M (Q3 2026) to $87.8M (Q3 2025).
Q3 2026 results → · How Acadia Pharmaceuticals makes money →